Clinical Trials in the Netherlands / NCT05786625
Active, not recruiting Observational

Bronchoscopic Microwave Ablation of Lung Tissue

NCT05786625 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2023-05-04
Last updated
2026-02-02

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

Ablation

Ablation: Bronchoscopy and microwave ablation of lung nodule

Study summary

The primary purpose of this study is to evaluate the safety and feasibility of the Creo Medical MicroBlate™ Flex AB1 instrument used with the AB1 electrosurgical system in patients undergoing bronchoscopic microwave ablation of peripheral lung nodules.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: The participant may enter the study if ALL of the following apply: The patient: 1. Has signed the informed consent form 2. Are ≥ 18 years old 3. Has lung lesion(s)/nodule(s) which are histologically confirmed or highly suspicious for cancer and is a candidate for bronchoscopic microwave ablation (as determined by a multi-disciplinary team (MDT) or tumour board). 4. Has a medically inoperable soft tissue lung lesion(s) ≤ 20 mm (suspected or confirmed malignancy), or patient has elected not to have surgery / alternative therapy. 5. Patient is a candidate for bronchoscopy under general anaesthesia. 6. Subject is willing and able to comply with the study protocol requirements. 7. Are assigned an ASA (American Society of Anaesthesiologists) score of ≤ 3 or the patient is deemed fit for general anaesthesia. Exclusion Criteria: The participant may not be enrolled in the study if ANY of the following apply: For patients undergoing procedures employing robotic-assisted bronchoscopy: 1\. a. Target nodule(s) are within 10mm of the trachea, right and left main bronchus, aorta, central pulmonary arteries, heart, oesophagus, spinal cord, phrenic \& laryngeal nerves. Note: Exclusion Criteria 1a is UK-specific. For patients undergoing procedures without the use of robotic-assisted bronchoscopy (manual procedures): 1. b. Target nodule(s) are within the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, oesophagus, spinal cord and phrenic and laryngeal nerves), or are \<10 mm from the pleura. 2. Are assigned status 4 via ECOG (Eastern Cooperative Oncology Group) classification. 3. Are pregnant or breast feeding, as determined by standard site practices. 4. Have participated in an investigational drug or device research study within 30 days of enrolment that would interfere with this study. 5. Are scheduled for concurrent interventional procedure for the target soft tissue lesion. 6. Have a physical or psychological condition or other factor(s) that would impair study participation, or jeopardise the safety or welfare of the subject. 7. Have an expected survival less than 6 months. 8. Have patients with bleeding diathesis, uncorrectable coagulopathy or platelet count ≤ 100 x 10⁹ /L. 9. Have an implantable devices, including pacemakers or other electronic implants. 10. Have known pulmonary hypertension (PASP \[pulmonary artery systolic pressure\] \> 50mmHg). 11. Who are currently prescribed anticoagulants, clopidogrel or other platelet aggregation inhibitors which cannot be stopped or temporarily withheld. 12. Any patient with clinically significant interstitial lung disease in the zone of planned ablation. Note: Exclusion Criteria 12 is NL-specific. 13. Patient has nodal disease confirmed through invasive or image-based staging. Note: if nodal disease is suspected or detected during the staging procedure conducted prior to use of the investigational device during the study procedure, the subject will be excluded. 14. Subject had a prior pneumonectomy.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Amsterdam University Medical Centres, Location AMC, Meibergdreef 9 Amsterdam Netherlands
Royal Brompton and Harefield NHS Foundation Trust London United Kingdom

More Creo Medical Limited trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05786625 on ClinicalTrials.gov ↗ ← All trials in the Netherlands